“Growing end” of inflammation discovered

Electron micrograph


of the junction between the danger sensor NLRP3 and its signal protein, shown in magnification with the calculated protein structure. CREDITImage: Inga V. Hochheiser

Redness, swelling, pain – these are signs of inflammation. It serves to protect the body from pathogens or foreign substances. Researchers from the Universities of Bonn and Cologne were able to show that inflammatory reactions of an important sensor protein proceed in a specific spatial direction. This finding has the potential to conceivably stop inflammation at the “growing end”, and thus bring chronic inflammatory diseases to a halt. The study has now been published in the journal “Science Advances“. 

If bacteria or viruses attack living cells or other foreign substances appear in them, the danger sensor with the abbreviation NLRP3 is activated. “The protein deposits in the brain that are characteristic of Alzheimer’s disease, the so-called amyloid-ß plaques, can also set NLRP3 in motion,” says Prof. Dr. Matthias Geyer from the Institute for Structural Biology at the University Hospital Bonn, referring to earlier studies. As these previous studies by the researcher’s show, this reaction increasingly fuels itself: The inflammatory reaction triggered by NLRP3 promotes the further deposition of amyloid-ß plaques and contributes significantly to the disease process.

Once activated, several NLRP3 proteins attach to each other and in this way form the nucleus for a thread-like structure at which more and more proteins gather. “The reaction kicks in as soon as about a dozen of the NLRP3 molecules are present,” Geyer reports. In theory, an infinite number of NLRP3 molecules can join together and extend the thread-like structure – scientifically called a “filament” – further and further. Inga Hochheiser from Prof. Geyer’s team has now been able to show the direction in which this filament grows and continues to expand. “We were able to gain these insights using cryo-electron microscopy. This method makes it possible to observe protein molecules with up to 80,000-fold magnification and thus make them directly visible,” says Hochheiser.

“Still image” of the thread-like structure under the microscope

In tiny steps, the scientist drizzled NLRP3 isolated from cells onto a sample carrier and flash-froze this mixture. This provided the researchers with a kind of “still image” under the cryo-electron microscope. The emerging thread-like structure of NLRP3 molecules arranged side by side was thus visualized. “These individual images made it possible to understand how the filaments elongate, just like in a film,” says Hochheiser. As the molecules fall differently on the sample carrier when drizzled, they can be seen from different perspectives under the microscope. These different views can be combined on the computer to create a three-dimensional image. The results showed that the filaments only form in one direction. “This allowed us to visualize part of the inflammatory apparatus and literally read the direction of growth,” says Prof. Geyer, who led the study and is a member of the Cluster of Excellence ImmunoSensation2 and the Transdisciplinary Research Area “Life and Health” at the University of Bonn.

Stopping chronic inflammatory diseases

“The technical challenge was to find the transitions in the thread-like structures and make them visible in the image,” says Prof. Dr. Elmar Behrmann from the Institute for Biochemistry at the University of Cologne. “The new findings now allow us to target the growing end of the inflammatory response using antibodies or drugs,” Hochheiser explains. This brings the researchers closer to their goal of stopping the further build-up of the inflammatory apparatus and thus counteracting chronic inflammation.

How one inflammatory disorder exacerbates another

With interactions in the bone marrow, inflammatory disorders exacerbate one another


Inflammation in the gums can increase susceptibility to other forms of inflammation, such as arthritis, through changes to immune cell precursors in the bone marrow, according to new research led by Penn scientists and collaborators. CREDIT Katie Vicari

The immune system remembers. Often this memory, primed by past encounters with threats like bacteria or viruses, is an asset. But when that memory is sparked by internal drivers, like chronic inflammation, it can prove detrimental, perpetuating a misguided immune response.

In a new paper in Cell, researchers from the School of Dental Medicine, together with an international team including colleagues at the Technical University of Dresden, lay out the mechanism by which innate immune memory can cause one type of inflammatory condition—in this example, gum disease—to increase susceptibility to another—here, arthritis—through alterations to immune cell precursors in the bone marrow. In a mouse model, the team demonstrated that recipients of a bone marrow transplant were predisposed to more severe arthritis if their donor had inflammatory gum disease.

“Although we use periodontitis and arthritis as our model, our findings go above and beyond these examples,” says George Hajishengallis, a professor in Penn Dental Medicine and a corresponding author on the work. “This is in fact a central mechanism, a unifying principle underlying the association between a variety of comorbidities.”

The researchers note that this mechanism may also prompt a reconsideration of how bone marrow donors are selected, as donors with certain types of immune memory caused by underlying inflammatory conditions might put bone marrow transplant recipients at a higher risk of inflammatory disorders.

Basis in the bone marrow

In previous work, Hajishengallis had partnered with co-corresponding author Triantafyllos Chavakis of Technical University of Dresden and collaborators to explore the role of innate immune memory. Their findings showed that, just like the adaptive immune system’s T cells and B cells, the innate immune system’s myeloid cells, such as neutrophils and macrophages, could “remember” past encounters, becoming more responsive when exposed to a new threat. The work also pinpointed how this memory was encoded, tracing it to the bone marrow, and showed that this “trained immunity” could be transferred from one organism to another through a bone marrow transplant, protecting recipients from cancer through an innate immune response. 

While that is good news, Hajishengallis and Chavakis also believed that trained immunity could be detrimental in the right contexts. While attending a meeting on innate immunity in Greece in 2019, the two scientists brainstormed over dinner at an outdoor tavern, jotting down their thoughts on a napkin. They later formalized some of their hypotheses about this potential “dark side” of trained immune in a publication in Nature Reviews Immunology in 2021.

“The thoughts went like this: We knew the gum disease periodontitis increased the risk of comorbidities like cardiovascular disease,” says Hajishengallis. “And the reverse is also true: People with the inflammatory disease colitis, for example, have an increased prevalence of periodontal disease. Different mechanisms have been proposed, but no one unifying mechanism could explain this bidirectionality.” 

“We started thinking about a possible unifying mechanism that could underlie the association between several distinct comorbidities,” says Chavakis. 

Building on their earlier discovery related to “trained” precursors in the bone marrow, the scientists set out to see whether they could trace the source of the association between comorbidities to the innate immune training they already knew was happening in the bone marrow.

Setting out to test this hypothesis, the team first showed that, within a week of inducing a mouse to have periodontal disease, the animal’s myeloid cells and their progenitor cells expanded in the bone marrow. Examining these cells weeks later, after periodontitis was intentionally resolved, the researchers did not notice significant changes in how the cells looked or behaved. 

However, these progenitor cells appeared to have memorized the inflammation they were exposed to, as they harbored important epigenetic changes: alterations in molecular markers that affect the ways genes are turned on and off but do not alter the actual DNA sequence. The researchers found that these alterations, triggered by inflammation, could alter the manner in which the genes would be expressed after a future challenge. The overall pattern of epigenetic changes, the researchers noted, was associated with known signatures of the inflammatory response.

Mice with induced periodontal disease also had more severe responses to a later immune system challenge, evidence of trained immunity.

To put the whole picture together regarding the link between inflammatory conditions, the “critical experiment,” as Hajishengallis explains, was a bone marrow transplant. Mice that had periodontitis, a severe form of gum disease, served as donors, as did a group of healthy mice serving as controls. Two hundred stem cells from their bone marrow were transplanted into mice that had never had gum disease and which had had their own bone marrow irradiated. A few months later, these mice were exposed to collagen antibodies, which trigger arthritis. 

“Mice that received the transplant from mice with periodontitis developed more severe arthritis than mice that received a donation of stem cells from periodontally healthy mice,” says Hajishengallis. 

“And higher joint inflammation in recipient mice was due to inflammatory cells deriving from the periodontitis-trained stem cells,” says Chavakis. 

Further experiments suggested that the signaling pathway governed by a receptor for the molecule IL-1 played a vital role in contributing to this inflammatory memory. Mice that lacked IL-1 receptor signaling could not generate the immune memory that made the recipient mice more susceptible to comorbidities, the researchers found. 

The work has implications for bone marrow transplants in humans, a common course of therapy in addressing blood cancers. 

“Of course, it’s a great thing if you find a matching donor for bone marrow transplantation,” says Hajishengallis. “But our findings suggest that it’s important for clinicians to keep in mind how the medical history of the donor is going to affect the health of the recipient.” 

The work also underscores that blocking IL-1 receptor signaling could be an effective approach to mitigate against these knock-on effects of trained immunity.

“We’ve seen anti-IL-1 antibodies used in clinical trials for atherosclerosis with excellent results,” Hajishengallis says. “It could be that it was in part because it was blocking this maladaptive trained immunity.”

Follow-up projects are examining how other inflammatory conditions, may be linked with periodontal disease, a sign, the researchers say, of how crucial oral health is to overall health.

“I’m proud for the field of dentistry that this work, with significance to a wide range of medical conditions, began by investigating oral health,” Hajishengallis says.

New approach against chronic inflammation

Graphics


ASC specks – shown here in different colors – are large complexes of many copies of the ASC protein. They can cause immense damage in the tissue. CREDIT © Franklin Lab / University of Bonn

Not only the villas of the rich and famous have a direct line to the police. The cells in our body also have a sophisticated alarm system, the inflammasome. Its central component is the so-called ASC protein. In the event of danger, such as an attack by a pathogen, many of these molecules join together to form a large complex, the ASC speck. This ensures two things: First, its activity causes the cell to accumulate large quantities of messenger substances, which can be used to summon the help of the immune system. And secondly, numerous pores are formed in the cell membrane through which these alarm molecules can reach the outside and fulfill their task.

Last cry for help from the dying cell

These holes ultimately lead to the demise of the cell: “At some point, the cell basically explodes and empties its entire contents into the tissue,” explains Prof. Dr. Bernardo Franklin of the Institute of Innate Immunity at the University Hospital Bonn. “The messenger substances that are now abruptly released then act like a last great cry for help. This triggers the immune system to mount a strong inflammatory response that contains the infection.” That is why this mechanism of innate immune defense is hugely important.

However, in this process, ASC specks also accumulate in the tissue and may persist there for a long time. “We have now been able to show in mice that their activity activates the immune system even after the threat has been averted,” Franklin says. “This can result in chronic inflammation, which severely damages the tissue.” Together with researchers from the University of Sao Paulo, Franklin’s team has succeeded in preventing this undesirable effect. They used so-called nanobodies for this purpose.

These agents are antibody fragments with a very simple structure. “In collaboration with Prof. Dr. Florian Schmidt from the Institute of Innate Immunity, we generated nanobodies that specifically target ASC and can dissolve the specks,” explains Franklin’s collaborator Dr. Damien Bertheloot. The researchers got help from an alpaca: They injected the animal with the ASC protein so that it developed matching antibodies. Some of the alpaca antibodies have a very simple structure. This makes it possible to produce and test fragments of these antibodies as so-called nanobodies.

Rheumatism and gout symptoms alleviated in mice

The researchers were able to obtain the genetic information for the ASC nanobodies from blood samples of the animal using a complex technique. “We then incorporated this genetic makeup into bacteria so that we could have them produce the nanobody in large quantities,” Bertheloot explains. The team demonstrated that the compound can dissolve ASC specks using human cell cultures as well as mice. “The mice in our experiments have rheumatoid and gout-like symptoms,” Bertheloot explains. “After administration of the nanobody, the inflammation and also the general health of the rodents improved significantly.”

Nanobodies are very small compared to normal antibodies. They are therefore excellent for breaking up such molecular complexes. This is because they can still reach sites that would be too cramped for large agents. Moreover, normal antibodies provide additional stimulation to the immune system and can therefore exacerbate inflammation – a property that nanobodies lack.

The results are also interesting for another reason: Studies indicate that ASC specks can also cause significant damage to the brain. There, they seem to serve as a kind of “crystallization nucleus” for the Aß protein. In the brains of Alzheimer’s patients, Aß clumps together to form large protein complexes called plaques. Presumably, ASC specks can trigger this clumping. “So perhaps it’s possible to slow down this process with the help of our nanobodies,” Franklin hopes. “We now plan to investigate this possibility in a follow-up study.” Bernardo Franklin is a member of the ImmunoSensation2 Cluster of Excellence at the University of Bonn.

At the same time, however, he warns against overly high expectations: Even in the ideal case, it will be years before the results might translate into new drugs.

Large genetic study uncovers potential new treatments for inflammatory diseases

Tie One on for Multiple Sclerosis


Researchers from the Research Centre of Applied and Preventive Cardiovascular Medicine at the University of Turku, Finland, have studied over ten million DNA variations and found new links between the human genome and inflammation tracers. The study uncovered new possibilities for treatment of diseases such as multiple sclerosis, Crohn’s disease and coeliac disease.

Cytokines and growth factors, which circulate in the bloodstream, are important proteins for regulating inflammation reactions. Changes in their mode of operation have been linked with many inflammatory diseases, such as Crohn’s disease, multiple sclerosis, atherosclerosis, ulcerative colitis and many types of cancer.

In this latest study, based on population data and coordinated by the University of Turku’s Research Centre of Applied and Preventive Cardiovascular Medicine, an investigation was made of the links between 41 different cytokines and growth factors and 10.7 million DNA variations.

? We wanted to find out the molecular-level processes that lead to an increased risk of developing inflammatory diseases. Understanding these processes will enable more effective treatment of diseases, explains Professor Olli Raitakari, Director of the Research Centre.

Researchers noticed that the medicine daclizumab, previously used for treating organ rejection reactions, could possibly also be used in the treatment of multiple sclerosis and Crohn’s disease. In addition, an increase in the activity of MIP1b-cytokine could also serve as a method of treatment against coeliac disease and Behcet disease. Further clinical studies are required to confirm the observations.

Evidence from human genetics speeds up medical development

Technological development has enabled the practice of genome-wide association studies since the turn of the century.

? In these kinds of studies, millions of DNA variations are examined and their impact is assessed for each property being studied. The studies carried out so far have succeeded in uncovering, for example, over one hundred genomic loci which have an impact on the risk of developing Crohn’s disease or ulcerous colitis.

In studies of connections between genetic variations and disease risks, the precise molecular process causing the increased risk often remains unclear. In order to uncover this molecular process, genome-wide association studies use as response variables molecules that mediate disease-risk through the bloodstream, such as cytokines and growth factors, instead of using the diseases themselves.

Structure of central inflammation switch elucidated

PhD student Inga Hochheiser and Prof. Dr. Matthias Geyer,


director of the Institute of Structural Biology at the University Hospital Bonn (UKB), looking at a cryo-electron microscopy carrier. Photo: Johann F. Saba/UKB

Researchers at the Universities of Bonn and Regensburg have elucidated the structure of a central cellular inflammatory switch. Their work shows which site of the giant protein called NLRP3 inhibitors can bind to. This opens the way to develop new pharmaceuticals that could target inflammatory diseases such as gout, type 2 diabetes or even Alzheimer’s disease. The results are published in the journal Nature

In their study, the researchers investigated a protein molecule with the cryptic abbreviation NLRP3. This is a kind of danger sensor in the cell: It sounds the alarm when the cell is under stress, such as from a bacterial infection or toxins.

NLRP3 then induces the formation of pores within the cellular membrane, which ultimately results in the cell’s death. Before that, however, the sensor molecule stimulates the formation of inflammatory messenger substances that are released through the perforated membrane. These so-called cytokines recruit more immune cells to the site and ensure that cells in the surrounding area commit suicide – thereby preventing a bacterium or virus from further spreading.

“The result is a massive inflammatory response,” explains study leader Prof. Dr. Matthias Geyer from the Institute of Structural Biology at the University of Bonn. “This is certainly very useful for the defense against pathogens. But if this response is overdosed or triggered by even harmless cues, it can lead to chronic inflammatory diseases – such as type II diabetes, gout, Crohn’s disease, or even dementias like Alzheimer’s.”

Targeted containment of inflammation

Researchers around the globe are therefore seeking for ways to target inflammatory processes without disrupting the entire mechanism of the immune response. As early as 20 years ago, the US pharmaceutical company Pfizer published an interesting finding in this regard: Certain active substances prevent the release of cytokines, the most important inflammatory messengers. How these CRIDs (Cytokine Release Inhibitory Drugs) do this, however, was unknown until now.

It has been known for several years that CRIDs somehow prevent cellular danger sensors from sounding the alarm. “We have now discovered the way in which they exert this effect,” explains Geyer’s colleague Inga Hochheiser. This involved isolating large amounts of NLRP3 from cells, purifying it, and adding the inhibitor CRID3. Hochheiser dropped minute portions of this mixture onto a carrier and then froze them rapidly.

This method creates a thin film of ice containing millions of NLRP3 molecules to which CRID3 is bound. These can be observed with an electron microscope. Since the molecules fall differently as they drop, different sides of them can be seen under the microscope. “These views can be combined to create a three-dimensional image,” Hochheiser explains.

The cryo-EM images allow a detailed insight into the structure of the hazard sensor inactivated by CRID3. They reveal that NLRP3 in its inactive form assembles into a mega-molecule. It consists of ten NLRP3 units that together form a kind of cage. “The most exciting result of our work, however, is that we were able to identify the CRID3 molecule docked into its binding site,” Geyer is pleased to report. “That was a tough nut that many groups worldwide have been trying to crack.”

Inhibitor prevents the activation of the giant molecule

The binding sites (structural biologists also speak of “pockets”) are located inside the cage. Each of the ten NLRP3 units has one of these pockets. When occupied by CRID3, the inhibitor blocks a flap mechanism required for NLRP3 activation. Similar to a blooming rose, which can only be visited by a bee in this state, certain parts of the NLRP3 protein reach the surface of the cage when the flap is turned over and thus become accessible.

NLRP3 is a representative of an entire family of similar proteins. Each of them presumably performs its very specific task in different inflammatory processes. “Based on our research, we believe that the pockets of all these NLRPs are different,” Geyer says. “A specific inhibitor can therefore probably be found for each of them.” This gives researchers a whole arsenal of potential new weapons against diverse, inflammatory diseases.

For example, the current work allows a targeted search for more effective alternatives to CRID3 that also have fewer side effects. But that is just the beginning, says Geyer, who is also a member of the ImmunoSensation2 Cluster of Excellence at the University of Bonn. “I am convinced that our study opens up a fruitful new field of research that will keep researchers busy for decades to come.”